Wells Fargo downgraded Verona Pharma (VRNA) to Equal Weight from Overweight with a price target of $107, down from $138, after Merck (MRK) announced it will acquire Verona for $10B or $107 per share. Wells does not see any other bidders as likely to come in.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Verona Pharma downgraded to Hold from Buy at TD Cowen
- Merck’s Acquisition of Verona Pharma Caps Stock’s Upside Potential, Downgraded to Hold
- Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
- Verona Pharma downgraded to Hold from Buy at Canaccord